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Chapter 5
Gd-TEMDO: Design, synthesis 
and MRI application 
André Boltjes, Annadka Shrinidhi, Kees van de Kolk , Eberhardt Herdtweck, 
and Alexander Dömling




A simple Ugi tetrazole multicomponent reaction allows the synthesis of a nov-
el macrocyclic cyclen derivative with four appendant tetrazole arms in just two 
steps in excellent yields. This ligand, called TEMDO, turns out to be a very good 
chelator of lanthanoid metals. Here we describe the design, synthesis, solid state 
structure, binding constant and some MRI applications of the Gd-TEMDO com-
plex as the first example of a congeneric family of oligo-amino tetrazoles.
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Introduction
Since its discovery in 1971 magnetic resonance imaging (MRI) has evolved into a 
medical imaging technique of major importance and has rapidly found its entry 
into daily clinical diagnostics.1 Today more than 20.000 MRI scanners are operat-
ing worldwide in hospitals and more than 50 million clinical MRI examinations 
are performed every year. The impact of this breakthrough technology for man-
kind was honored by the Nobel Prize in Physiology or Medicine in 2003.2-3 As 
opposed to other imaging techniques, MRI is a non-ionizing radiation method 
and is therefore widely used in medical diagnosis and staging of disease. While 
MRI in principle does not require contrast agents, its use dramatically accelerates 
acquisition times and signal intensity. MRI contrast agents work by accelerating 
the relaxation of water protons in the surrounding tissues. Paramagnetic ions 
are suitable contrast agents and amongst them gadolinium (Gd3+) complexes are 
by far the most widely used MRI contrast agents due to its seven unpaired elec-
trons, its slow electronic relaxation and its exquisite complex stability. Although 
clinically approved MRI contrast agents are generally considered as safe, a small 
number of fatalities were reported likely due to nephron- and neurotoxicity by 
Gd-leaking.4 In addition, not only patients with pre-existing renal failure are af-
fected by Gd-leakage, but also patients with other conditions showed consid-
erable neuronal tissue concentrations of Gd3+ after being subjected to Gd-based 
contrast agents (GBCA’s).5
Here we introduce the first example of the novel class of oligoamino tetrazoles 
as chelating agent useful in imaging: 1,4,7,10-tetrakis((1H-tetrazol-5-yl)meth-
yl)-1,4,7,10-tetraazacyclo-dodecane (TEMDO, 3) (scheme 1). We describe the de-
sign, synthesis, solid state structure, binding constant and some MRI applica-
tions of the Gd-TEMDO complex.
The tetrazole is a known bioisostere of the carboxylic acid with often superior 
PKPD properties.6 For example the tetrazolate allows for a more wide delocal-
ization of the negative charge and could thus facilitate better penetration into 
tissue. In the context of MRI a tetrazolate ligand could also help to increase pro-
ton relaxivity through changes in the metal-H distance by electron delocalization 
towards the ligand. Moreover through subtle changes in the ligand composition 
and geometry eventually higher tilt angles between the plane of the bound water 
and the metal–O bond could be induced by hydrogen bonding of the coordinated 
water to an appropriate side group of the chelate, which could potentially result 
in a significant decrease of the metal–proton distance. Thus we reasoned that 
oligoamino tetrazoles are suitable for MRI, exhibiting different and eventually 
better physicochemical and biological properties compared to their carboxylic 
acid analogues. Surprisingly oligoamino tetrazoles in general and specifically as 
MRI agents are unknown.7 Based on our longstanding expertise in multicompo-
nent reaction (MCR) chemistry and its versatility, speed and ease-to-perform we 
choose MCR as a perfect tool to assemble this functional material class of MRI 
agents.8-9 As a first synthetic target of the class of the oligoamino tetrazoles (2) we 




Scheme 1. DOTA, general formula of oligo-amino tetrazoles, TEMDO and retro synthesis 
thereof.
Results and Discussion
In our retrosynthesis we envisioned that TEMDO can be fast and convergently 
synthesized by applying a Ugi tetrazole reaction from available cyclen.12 The un-
protected TEMDO ligand suitable for metal complexation has to be generated by 
cleavage of the isocyanide substituent. In principle several cleavable isocyanides 
such as Walborsky’s, benzyl- or tert-butyl are suitable, however we have chosen 
here β-cyanoethyl isocyanide 4 due to its cleavage under mild conditions.
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Scheme 2. Two step UT-4CR MCR synthesis of the TEMDO ligand 3
In fact after some optimization of the reaction conditions we could obtain the Ugi 
tetrazole product 8 in quantitative yields by reacting the commercially available 
starting materials cyclen 5, paraformaldehyde 6, and TMS azide 7, as a safe hy-
drogen azide source and β-cyanoethyl isocyanide 4 (scheme 2). The four β-cyano-
ethyl groups can be cleaved under mild conditions using NaOH in acetonitrile/
water at room temperature. The crude product was purified by precipitation at 
pH = 7.75, to give neutral TEMDO ligand (86%) in high purity. Next the chelating 
property of TEMDO towards the lanthanide element Gadolinium was assessed. 
The Gd3+ complex of TEMDO was prepared by either a) heating the 1:1.1 mix-
ture of TEMDO ligand and GdCl3 in water at 70 °C for 7 days at pH 6.7, or by b) 
heating TEMDO (in acidic form), the approved excipient meglumin and GdCl3 
1:1:1 in water for 7 days at 70 °C. The remaining free Gd3+ was removed using 
ion-exchange resin Chelex®-100 and the clean liquid was lyophilized to get pure 











































Scheme 3. Reaction scheme of the formation of Gd-TEMDO complex, the counter ion sodium or me-
glumine is present depending on the method of preparation.
Then we investigated the complex-behaviour of TEMDO towards the lanthanide 
element Gadolinium by determining its solid state 3D structure using X-ray crys-
tallography. The complex crystallized in small rhombic shapes from water and 
the solved structure is shown in figure 1. The side by side comparison of the 
obtained crystal structure of Gd-TEMDO with the Gd-DOTA complex shows a 
surprisingly high isosterism (figure 1).
Figure 1. A stick representation of the crystal structures (unbound crystal waters and 
counterions are omitted for clarity). Above row: top down view; below row: side on view; 
left; Gd-DOTA.
The central Gd3+ ion is surrounded by the four basal cyclen-N and apical by the 
four N1 of the appendant tetrazoles in a highly symmetrical twisted quadratic 
coordination sphere. In addition a water molecule is coordinated on top of the 
twisted cube in-between the four tetrazole ligands. The coordination number for 
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Gd3+ is therefore 9 and the idealized complex belongs to the chiral point group 
C4. In principle 9-fold coordinated Ln-complexes with C4 symmetry can present 
a square anti-prismatic (SAP) or twisted square antiprismatic (TSAP) geometry. 
Moreover due to their membership to the chiral C4 point group Ln-TEMDO com-
plexes can show the absolute chirality Λ (left-handed) or Δ (right-handed). The 
coordination geometry of the Gd-TEMDO and Eu-TEMDO complexes is square 
antiprismatic (SAP), whereas in the La-TEMDO we have found twisted square 
antiprismatic (TSAP) geometry. For example SAP geometry is the predominant 
form found for the Gd-DOTA complex in aqueous solution, besides some twisted 
square antiprism.7 Interestingly the X-ray structures of the Gd- and Eu-TEMDO 
reveal only one SAP enantiomer per crystal, while La-TEMDO is present in a 
TSAP geometry and both Λ and Δ enantiomers are present in one crystal (SI). 
Similarly in Ln-DOTA complexes SAP geometry is preferred over TSAP with 
increasing ionic lanthanide radius.13 The complex geometry is an important pa-
rameter in MRI active Ln complexes as the water exchange kinetics are linked 
to its geometry and relaxivity.14 Compared to TSAP, a SAP geometry will result 
in slower water exchange, but surprisingly a faster relaxation.15 The comparable 
size of the macrocyclic cavity of DOTA and TEMDO indicates that suitable metal 
ions will very well fit to form thermodynamically stable chelates.16 Qualitative 
assessment of free lanthanide ions with indicator xylenol orange showed that 
chelating generally occurs for the lanthanides. In table 1 we compare some key 
distances between Gd3+ with DOTA and TEMDO and its coordination towards 
N, and O as shown in solid state. The similarity of the alignment between Gd3+ 
and the both complexators DOTA and TEMDO expressed in distances gives an 
average difference of 0.09 Å RMSD. Such minor changes in bond length and an-
gle, however, can have profound effects on how well the ion is held, the residence 
time of the water molecule and its exchange rate.17
Table 1. M-O, M-N and M-N’ bond lengths in the 9-coordinated 
Gd-DOTA and TEMDO complexes. 
Complex M-N (Å)[a] M-O (Å)[b] M-N’ (Å)[c] M-O’[d]
[Gd(TEMDO)(H2O)]− 2,712 - 2,475 2.434
[La(TEMDO)(H2O)]− 2,780 - 2,616 2.507
[Gd(DOTA)(H2O)]− 2,648 2,377 - 2.458
[a] N represents the basal rim nitrogen’s. [b] Metal coordination to the four 
surrounding carboxylates [c] Metal coordination to the tetrazoles nitrogen [d] 
Average distance between the metal and water molecule..
The chelating properties of Gd-TEMDO were accessed by determination of the 
thermodynamic stability constant using colorimetry (table 1).18 The stability con-
stant 16.6 confirms the strong chelating properties of the macrocyclic TEMDO, 
similar to Gd-(DTPA-BMA), a marketed MRI contrast agent (Omniscan, 16.8), 
however lower than Gd-DOTA. Studies on Gd3+ release revealed that not only 
thermodynamic stability, but also kinetic inertness and elimination rate of the 
complex plays an important role in the amount of free Gd3+ in vivo.15 Kinetic in-
ertness expressed as dissociation rate is therefore important to predict toxicity 
through Gd3+ leakage (table 2). However, due to the general observed fast excre-
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tion of Gd-based contrast agents the complex is not long enough in the body to 
establish thermodynamic equilibrium. The lower stability constant of Gd-TEM-
DO as compared to the DOTA complex is thus compensated by a two orders of 
magnitude slower release of Gd3+ from the TEMDO complex
Table 2. Binding constants and kinetic data of Gd3+ complexes.
Metal Complex Log K  [a]  [b]
[Gd(TEMDO)(H2O)]− 16.6 3.47 ± 0.5 x 103 1.20 ± 0.5 x 10-8
[Gd(DOTA)(H2O)]− 24.1[c] 5.16 ± 0.5 x 103 3.20 ± 0.5 x 10-6
[a] Formation rate, experimentally determined for both TEMDO and 
DOTA by UV/VIS spectrometry [b] Dissociation rate [c] Value under 
identical conditions determined as for TEMDO (lit. value for Gd-DOTA 
24.719).
  
Finally we investigated the usefulness of Gd-TEMDO for magnetic resonance 
imaging. In a Bruker 9.4 T 400 MHz small bore MRI apparatus, we ran relaxation 
experiments resulting in phantom images of Gd-TEMDO (figure 2). From the 
phantom images we calculated a relaxivity r1 of 2.0 mM-1 s-1 which is in compari-
son with Gd-DOTA 6.0 mM-1 s-1 (measured under identical conditions at ambient 
temperature) somewhat lower, but being in the same range a promising starting 
point for further introduction of variations on TEMDO. The T1-weighted imag-
es as expected show, however a concentration dependent increase of the relax-
ation rate of the solvent water protons associated with Gd-based contrast agents. 
In-vivo assessment of Gd-TEMDO was performed via delayed contrast-enhanced 
MRI. Some Gd-based contrast agents such as Gd-DOTA accumulate in damaged 
myocardium tissues, diffusing from the intravascular into the interstitial space, 
unable to enter intact cells. Delay in measurement causes the majority of agent 
to wash out, and contrast agent absorbed in damaged tissue provides enhanced 
contrast.20 In a left-coronary-artery occlusion murine animal model we investi-
gated Gd-TEMDO to image the myocardial infarcted tissue. This clearly shows 
that the TEMDO contrast agent is absorbed in damaged tissue and the enhanced 
contrast is shown in figure 2.
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5Figure 2. Gd-TEMDO MRI. (a) T1-weighted MRI phantoms of Gd-TEMDO proving con-centration dependent T1 shortening. (b) MRI obtained from isoflurane-anaesthetized mice, (c) taken 30 minutes after I.P. administration of Gd-TEMDO (0.6 mmol/kg). Left: the heart 
fully visible; right: heart with reduced brightness, the damaged tissue remains visible due 
to absorbed Gd-TEMDO following the red line.
Conclusions
In summary, we have described design, synthesis, X-ray structure, binding and 
some applications of the first example of a new class of Ln chelators with poten-
tial for use in MRI as Gd-based contrast agents. The macrocyclic TEMDO ligand 
is easy accessible by only two synthetic steps, in excellent yields employing a Ugi 
tetrazole multicomponent reaction. The thermodynamic stability constant of our 
first Gd3+ complex is comparable to clinically used Gd-(DTPA-BMA). So far we 
were able to grow diffractable crystals of the Gd(III), Eu(III) and La(III) complex-
es. Moreover we were able to show proof-of-principle, utilizing the Gd-TEMDO 
complex as contrast agent and visualizing myocardial infarcts in mice. Further 
analysis of the complex confirms comparable structural features as compared to 
marketed Gd-based contrast agents, a very good starting point for future devel-
opment of this new class of oligotetrazolo-based metal complexes.
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Experimental procedures and Spectral Data
Instruments employed: Electrothermal digital melting point apparatus; Bruker 
Avance DRX 500 MHz NMR spectrometer (B AV-500) equipped with Bruker Au-
tomatic Sample Changer (BACS 60). For MRI; Bruker 9.4T 89mm bore scanner 
equipped with 1500mT/m gradientset. Thar SFC-MS equipped with autosampler 
and autoinjector; pH meter pHenomenal® with Thermo Scientific Orion ROSS 
Ultra pH electrode; Jasco V-660 UV-VIS Spectrophotometer. High resolution 
mass spectra were recorded using a LTQ-Orbitrap-XL (Thermo) at a resolution 
of 60000@m/z400.
Chemicals required: DOTA, paraformaldehyde, sodium hydroxide, potassium 
chloride, potassium hydrogen phthalate, ethylene diamine tetraacetic acid, KOH 
concentrate (Sigma-Aldrich); Arsenazo III (TCI); 1,4,7,10-tetraazacyclododecane, 
azidotrimethylsilane, gadolinium chloride anhydrous (ABCR); phenolphthalein, 
xylenol orange (Fluka); acetic acid (Acros), sodium acetate (Merck); hydrochlo-
ric acid, methanol, acetonitrile (Boomlab) were obtained commercially and used 
without any further purification. 3-Isocyanopropanenitrile was prepared in the 
laboratory from its corresponding formamide. Millipore water was used for the 
preparation of all solutions. 
NMR spectra were recorded in CDCl3 (with 0.03% TMS), DMSO-d6 and D2O 
(with 0.03% DSS) at either 500 MHz (δH) or 125 MHz (δC); the coupling constants 
(J) are in Hz. Abbreviations: mp (melting point), s (singlet); d (doublet); t (triplet); 
q (quartet); br (broad); dd (doublet of doublet), etc. The nomenclatures of all the 
compounds were derived by ChemDraw (CambridgeSoft). 
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In a 50 mL roundbottom flask was added parafor-
maldehyde (3.0 g, 100 mmol), 1,4,7,10-tetraazacyclo-
dodecane (0,861 g, 5 mmol), azidotrimethylsilane 
(6,6 mL, 50 mmol) and 3-isocyanopropanenitrile (2,0 
g, 25,00 mmol) in methanol (15 mL) to give a yellow 
suspension. Stirring overnight, removing the sol-
vent by decantation, redissolving in 20 mL acetoni-
trile, filtering over Celite® and concentrating under 
reduced pressure yields 
3,3’,3’’,3’’’-(5,5’,5’’,5’’’-((1,4,7,10-tetraazacyclodo-
decane-1,4,7,10-tetrayl)tetrakis(methylene))tetrakis(1H-tetrazole-5,1-diyl))tet-
rapropanenitrile, (3.58 g, 100%) as an orange oil. 1H NMR (500 MHz, DMSO-d6) δ 
4.75 (t, J = 6.4, 8H), 3.95 (s, 8H), 3.22 (t, J = 6.4, 8H), 2.69 (s, 16H) ppm. 13C NMR 
(125 MHz, DMSO-d6) δ 152.9, 118.0, 50.9, 46.3, 42.5, 17.8 ppm. HRMS (ESI) m/z 



















In a 100 mL roundbottom flask was added 
3,3’,3’’,3’’’-(5,5’,5’’,5’’’-((1,4,7,10-tetraazacyclododec-
ane-1,4,7,10-tetrayl)tetrakis(methylene))tetrakis(1H-
tetrazole-5,1-diyl))tetrapropanenitrile (7) (2.0 g, 2,8 
mmol) and NaOH (1,80 g, 22,5 mmol) in acetonitrile-wa-
ter (5:1, 20 mL) to give a yellow solution. After stirring 
overnight at room temperature, the solvent was evapo-
rated from the reaction mixture and the solid mass was 
dissolved in 75 mL water. The pH of solution was ad-
justed to 7.0 with aqueous HCl. This neutral solution was extracted with di-
chloromethane (2 x 25 mL) to remove organic impurities. The aqueous layer was 
lyophilized and redissolved in 100 mL methanol and undissolved solid mass was 
removed by filtration. The supernatant liquid was evaporated to dryness, redis-
solved in 5 mL water and the pH was adjusted 7.75 with aqueous NaOH. A white 
solid precipitated and was collected by filtration, washed with cold water and 
dried to obtain 1.26 g (86%) of TEMDO. m.p.>300°C. 1H NMR (500 MHz, D2O) δ 
4.20 (s, 8H), 2.87 (s, 16H). 13C NMR (125 MHz, D2O) δ 160.0, 52.4, 49.7 ppm. HRMS 























The Gd3+ complex of TEMDO was prepared by heating 
the 1:1.1 mixture of TEMDO ligand (3) (1.0 g, 2.0 mmol) 
and GdCl3∙6H2O (0.82 g, 2.2 mmol) in 20 mL Millipore 
water at 70°C for 10 days at pH 6.8. The remaining free 
Gd3+ was removed using Chelex 100 and the clean liquid 
was lyophilized to give pure Gd-TEMDO complex as a 
white solid (>98%, 1.28g). Complexes for Eu and La 
were prepared in the same manner. HRMS (ESI) m/z 




N O A solution of 3-aminopropionitrile (10g, 143 mmol) in ethyl formate 
(250 mL, 143 mmol) was refluxed for 5 hours. The mixture was con-
centrated in vacuo, yielding 13,9g, 99% as a yellow oil. The product 
is obtained as a mixture of two amide rotamers. 1H NMR (500 MHz, DMSO-d6): 
δ = 8.22 (s, 1H, major), 6.97 (s, 1H, major), 3.57 (tt, J=9.0, 4.3, 2H), 2.79 – 2.61 (m, 
2H) ppm. 13C NMR (125 MHz, CDCl3) δ 162.1, 118.2, 37.9, 34.3, 20.5, 18.4 ppm.
3-isocyanopropanenitrile (4)
NC
NC To a cold (0 °C) solution of N-(2-cyanoethyl)formamide (8.65g, 
88mmol) and triethylamine (61 mL, 441 mmol) in DCM was added 
drop wise over 60 min. POCl3 (8.2 mL, 88 mmol). After the addition the reaction 
was stirred at 0 °C for 2.5 hours. Then, carefully, 10% Na2CO3 was added fol-
lowed by water (200 mL) to dissolve all solids. The organic layer was separated 
and the water layer extracted with DCM (3 × 25 mL). The combined organic lay-
ers were washed with brine (100 mL), dried over MgSO4, and concentrated in 
vacuo. The crude dark brown residue was purified by passing it through a plug of 
silica (100% DCM). After evaporation of all volatiles the product (4.2g, 59%) was 
obtained as a brown oil which solidified upon standing. 1H NMR (500 MHz, 
CDCl3) δ 3.73 (t, J = 6.7 Hz, 2H), 2.81 (t, J = 6.7 Hz, 2H) ppm. 13C NMR (125 MHz, 
CDCl3) δ 160.1, 115.8, 37.7, 37.6, 37.6, 18.8 ppm.
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1H-NMR and 13C-NMR of the protected UT-4CR product 8 and the deprotected 
tetrazoles of TEMDO 3. The simplicity of the spectra confirms the four-fold sub-
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Crystallographic data
Data were collected on an X-ray single crystal diffractometer equipped with a 
CCD detector (Bruker APEX II, κ-CCD), a fine-focus sealed tube (Bruker AXS, 
D8) with MoK
α
 radiation (λ = 0.71073 Å), and a graphite monochromator by using 
the SMART software package. The measurements were performed on a single 
crystal coated with perfluorinated ether. The crystal was fixed on the top of a 
cactus prickle (Opuntia ficus-india) and transferred to the diffractometer. The 
crystal was frozen under a stream of cold nitrogen. A matrix scan was used to de-
termine the initial lattice parameters. Reflections were merged and corrected for 
Lorenz and polarization effects, scan speed, and background using SAINT. Ab-
sorption corrections, including odd and even ordered spherical harmonics were 
performed using SADABS. Space group assignments were based upon system-
atic absences, E statistics, and successful refinement of the structures. Structures 
were solved by direct methods with the aid of successive difference Fourier maps, 
and were refined against all data using WinGX based on SIR-92 in conjunction 
with SHELXL-97.33-34 C–H atoms were placed in calculated positions and refined 
using a riding model, with C–H distances of 0.99 Å, and Uiso(H) = 1.2·Ueq(C). O–H 
atoms were placed in calculated positions, with O–H distances of 0.84 Å, and 
Uiso(H) = 1.5·Ueq(O). Full-matrix least-squares refinements were carried out by mini-
mizing Σw(Fo2-Fc2)2 with SHELXL-97 weighting scheme. Neutral atom scattering 
factors for all atoms and anomalous dispersion corrections for the non-hydrogen 
atoms were taken from International Tables for Crystallography. Images of the crys-
tal structures were generated by PLATON. CCDC 1039908 (La-TEMDO) contains 
the supplementary crystallographic data for this compound. This data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 




Figure 3. – Ortep drawing of compound La-TEMDO with 50% ellipsoids. Full refinement 
was possible without running into problems. The atom O7 – crystal water was refined 
with an isotropic displacement parameter.
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Table 2. Data collection and refinement parameters of obtained crystals. The crys-
tal quality of Gd-TEMDO and Eu-TEMDO was not sufficient for full refinement.
Data Collection
La-TEMDO Gd-TEMDO (9) Eu-TEMDO
Molecular Formula C32H70La2N40Na2O11 C16H5GdN20NaO3+n C16H54EuN20NaO3+n
Molecular Weight 1515.08 g/mol 946.79 g/mol 464.59 a.m.u
Crystal Color/ size 0.13×0.15×0.25 mm 0.28×0.41×0.51 mm 0.10×0.30×0.36 mm






Cell Constants a =11.1804 Å 
b =17.6279 Å β = 91.9317° 
c =14.6590(4) Å 
V = 2887.46(15) Å3 
Z = 2  
Dcalc = 1.743 gcm-3
a =9.6950Å 
b =9.6950(4) Å 
c =20.3549(9) Å 
V = 1913.22(14) Å3  
Z = 2 
Dcalc = 1.59 gcm-3
a =9.8064 Å 
b =3.71307 Å 
β=90.2319(10)°
c =9.5809(2) Å




























Figure 4. – Ortep drawing of compound Gd-TEMDO with 50% ellipsoids. 
Figure 5. – Ortep drawing of compound Eu-TEMDO with 50% ellipsoids.
92
Gd-TEMDO: Design, synthesis and MRI application
5
References
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